Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

Annual dilated eye exam helps prevent vision loss in people with diabetes

Diabetes causes more new cases of legal blindness among working-age Americans than any other disease. If diabetics are monitored regularly by their ophthalmologist, this vision loss is almost always avoidable. Yet, tragically, more than half of all people living with diabetes do not get the recommended annual dilated eye exam.

30 Oct 2009

sanofi-aventis reports financial results for the third quarter of 2009

In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.

30 Oct 2009

Monash University physiologist honored with Life Scientist of the Year award

A Monash University physiologist, whose research into weight management, obesity and diabetes has led to significant medical breakthroughs and drug design, has been awarded one of the nation's top research honours.

30 Oct 2009

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.

30 Oct 2009

New state-of-the-art biotechnology center opened on the West Coast

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

30 Oct 2009

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

The La Jolla Institute for Allergy & Immunology, an international leader in immunology research and San Diego's only research institute focused solely on immune-mediated diseases, today will dedicate its new Elam Discovery Wall and Type 1 Diabetes Center, which will focus on research into novel immunological-focused approaches to type 1 diabetes.

30 Oct 2009

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

Two teams of UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their stem cell based strategies for treating diabetes and brain tumors.

30 Oct 2009

NCDP to help bring dramatic improvement in the prevention and care of diabetes

The American Clinical Laboratory Association's Results for Life Campaign (RFL) today recognized the National Changing Diabetes Program (NCDP) for funding a newly published study on quality measurement in diabetes care.

30 Oct 2009

Healthy eating tips for diabetics

A new case of diabetes strikes every 20 seconds. With nearly 24 million Americans of all ages affected by the disease and an additional 57 million at risk for diabetes, diabetes has reached epidemic proportions.(1) If current trends continue, one out of three children will live with diabetes sometime in their future.

30 Oct 2009

VIVUS presents additional data on Qnexa Phase 3 trials

VIVUS, Inc. today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009.

30 Oct 2009

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

Human Genome Sciences, Inc. today announced financial results for the quarter ended September 30, 2009, and provided highlights of recent key developments.

30 Oct 2009

Aerobics and resistance training exercise prevent visceral fat gain

A study conducted by exercise physiologists in the University of Alabama at Birmingham (UAB) Department of Human Studies finds that as little as 80 minutes a week of aerobic or resistance training helps not only to prevent weight gain, but also to inhibit a regain of harmful visceral fat one year after weight loss.

30 Oct 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

Proper diet and exercise reduce risk of type 2 diabetes

Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent over 10 years in people at high risk for the disease.

29 Oct 2009

Aerobic exercise not only prevents weight gain, but also inhibits regain of harmful visceral fat

29 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

Go Daddy is the title sponsor of JDRF "Walk to Cure Diabetes"

For the third consecutive year, Go Daddy is the title sponsor of the Juvenile Diabetes Research Foundation International (JDRF) Walk to Cure Diabetes. The JDRF walk is this Saturday at Tempe Town Lake.

28 Oct 2009